Equities Analysts Offer Predictions for BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Research analysts at HC Wainwright issued their FY2026 earnings per share estimates for Bicara Therapeutics in a report issued on Friday, May 16th. HC Wainwright analyst R. Burns expects that the company will earn ($2.59) per share for the year. HC Wainwright has a "Buy" rating and a $41.00 price target on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share.

Several other equities analysts have also issued reports on BCAX. Wedbush reaffirmed an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wells Fargo & Company began coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target on the stock. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $32.00.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $14.47 on Monday. Bicara Therapeutics has a 1-year low of $8.91 and a 1-year high of $28.09. The firm has a fifty day moving average price of $12.81 and a 200 day moving average price of $15.20.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28).

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Woodline Partners LP raised its stake in Bicara Therapeutics by 26.5% during the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company's stock valued at $4,543,000 after acquiring an additional 72,998 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Bicara Therapeutics in the first quarter valued at approximately $248,000. Vestal Point Capital LP raised its stake in shares of Bicara Therapeutics by 290.0% during the first quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock worth $36,080,000 after purchasing an additional 2,058,975 shares during the last quarter. Braidwell LP raised its stake in shares of Bicara Therapeutics by 8.1% during the first quarter. Braidwell LP now owns 2,162,803 shares of the company's stock worth $28,181,000 after purchasing an additional 162,144 shares during the last quarter. Finally, DAFNA Capital Management LLC lifted its holdings in shares of Bicara Therapeutics by 100.9% during the first quarter. DAFNA Capital Management LLC now owns 212,001 shares of the company's stock worth $2,762,000 after purchasing an additional 106,501 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.